101
Views
22
CrossRef citations to date
0
Altmetric
Review

Management of bone metastases in refractory prostate cancer – role of denosumab

, &
Pages 363-372 | Published online: 17 Sep 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (21)

Max Christenson, Chung-Seog Song, Ya-Guang Liu & Bandana Chatterjee. (2022) Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized Therapy. Cancers 14:4, pages 892.
Crossref
Konstantin Horas & Markus J. Seibel. 2022. Bone Cancer. Bone Cancer 413 429 .
Bradley M. Turner & David G. Hicks. 2022. Bone Cancer. Bone Cancer 771 782 .
Oliver Trusler, Jacob Goodwin & Andrew L. Laslett. (2021) BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1875:1, pages 188459.
Crossref
Gary Gustavsen, Kelsey Taylor, Doria Cole, Laura Gullet & Nicolas Lewine. (2020) Health economic impact of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Future Oncology 16:36, pages 3061-3074.
Crossref
Eric Ballon-Landa, Justine Panian, Ithaar H. Derweesh & Rana R. McKay. (2020) Management of bone complications in patients with genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations 38:3, pages 94-104.
Crossref
Gary Gustavsen, Laura Gullet, Doria Cole, Nicolas Lewine & Jay T Bishoff. (2020) Economic burden of illness associated with localized prostate cancer in the United States. Future Oncology 16:1, pages 4265-4277.
Crossref
Sun H. Park, Evan T. Keller & Yusuke Shiozawa. (2017) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcified Tissue International 102:2, pages 152-162.
Crossref
Ping Tang & David G. Hicks. 2015. Bone Cancer. Bone Cancer 461 470 .
Markus J. Seibel. 2015. Bone Cancer. Bone Cancer 123 138 .
Maha Hussain, Paul G. Corn, M. Dror Michaelson, Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, Justine Y. Bruce, Susan Moran, Shih-Yuan Lee, H. Mark Lin & Daniel J. George. (2014) Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen. Clinical Cancer Research 20:16, pages 4218-4227.
Crossref
Candice Yong, Eberechukwu Onukwugha & C. Daniel Mullins. (2014) Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Current Opinion in Oncology 26:3, pages 274-283.
Crossref
Wei-Xiang Qi, Li-Na Tang, Ai-Na He, Yang Yao & Zan Shen. (2013) Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. International Journal of Clinical Oncology 19:2, pages 403-410.
Crossref
Zanjing Zhai, Xinhua Qu, Wei Yan, Haowei Li, Guangwang Liu, Xuqiang Liu, Tingting Tang, An Qin & Kerong Dai. (2014) Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling. Breast Cancer Research and Treatment 144:1, pages 33-45.
Crossref
Shahrzad Rafiei & Svetlana V Komarova. (2013) Molecular Signaling Pathways Mediating Osteoclastogenesis Induced by Prostate Cancer Cells. BMC Cancer 13:1.
Crossref
Akiko KukitaToshio Kukita. (2013) Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis. Future Oncology 9:11, pages 1609-1622.
Crossref
Cheng Yang, Gui-Sheng Qi, Rui-Ming Rong & Jian He. (2013) Clinical features and treatment strategies for older prostate cancer patients with bone metastasis. Asian Journal of Andrology 15:6, pages 759-763.
Crossref
Isla P. Garraway. (2013) Targeting the RANKL Pathway: Putting the Brakes on Prostate Cancer Progression in Bone. Journal of Clinical Oncology 31:30, pages 3838-3840.
Crossref
LIN XU, ZHU WANG, XIAO-FEI LI, XIA HE, LIN-LIN GUAN, JIU-LING TUO, YANG WANG, YANFEN LUO, HUI-LING ZHONG, SHAO-PENG QIU & KAI-YUAN CAO. (2013) Screening and identification of significant genes related to tumor metastasis and PSMA in prostate cancer using microarray analysis. Oncology Reports 30:4, pages 1920-1928.
Crossref
C. Monneret. (2013) Actualités thérapeutiques : l’abiratérone, le bélatacept, le vandétanib et la fidaxomycine. Annales Pharmaceutiques Françaises 71:2, pages 95-103.
Crossref
Sathana DushyanthenDavina A.F. CossignyGerald M.Y. Quan. (2013) The Osteoblastic and Osteoclastic Interactions in Spinal Metastases Secondary to Prostate Cancer. Cancer Growth and Metastasis 6, pages CGM.S12769.
Crossref